Notably, preclinical evidence suggests synergistic effects when EA is combined with metformin, significantly improving hepatic AMPK expression, liver morphology, and fibrosis compared to either intervention alone (73), positioning EA as a potential adjunct to pharmacotherapy in comprehensive MASLD management
Reduced GLP-1 levels are directly associated with development of metabolic disorders, including type 2 diabetes and obesity
This is why having both is so critical
Weight Loss: The average percent weight loss from patients starting weight after these 17 months at the maintenance dose was: -15% weight loss from baseline body weight at 68 weeks at the 2.4mg dose -In a two year follow up study, those who continued to take semaglutide at the 2.4mg dose were able to maintain an average of 15.2% of their initial weight
[DOI] [PubMed] [Google Scholar] 27.Al-Sabah S, Donnelly D
Peer-reviewed publications and clinical trial registries provide authoritative information